Inadequate presentation of tumor antigens by host professional antigen–presenting cells (APCs),
including dendritic cells (DCs), is one potential mechanism for the escape of tumors …

Background Nivolumab has been associated with longer overall survival than docetaxel
among patients with previously treated non–small-cell lung cancer (NSCLC). In an open-label …

Background First-line nivolumab plus ipilimumab has shown improved overall survival in
patients with advanced non-small-cell lung cancer (NSCLC). We aimed to investigate whether …

Purpose Chromosomal rearrangements involving the ROS1 receptor tyrosine kinase gene
have recently been described in a subset of non–small-cell lung cancers (NSCLCs). Because …

Defective dendritic cell (DC) function caused by abnormal differentiation of these cells is an
important mechanism of tumor escape from immune system control. Previously, we have …

Purpose Programmed death 1 is an immune checkpoint that suppresses antitumor immunity.
Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint …

We demonstrate a novel tumor-promoting role of myeloid immune suppressor Gr+CD11b+
cells, which are evident in cancer patients and tumor-bearing animals. These cells constitute …

Defective function of dendritic cells (DC) in cancer has been recently described and may
represent one of the mechanisms of tumor evasion from immune system control. We have …

Aberrant TGFβ signaling is common in human cancers and contributes to tumor metastasis.
Here, we demonstrate that Gr-1+CD11b+ myeloid cells are recruited into mammary …

Defective dendritic cell (DC) function has been described previously in cancer patients and
tumor-bearing mice. It can be an important factor in the escape of tumors from immune …